GLPwatch
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide
NCT00803920 · Completed
Last updated 2026-05-28This trial is testing how well a continuous glucose monitor (CGM) tracks blood sugar levels in adults with type 2 diabetes who are already taking either twice-daily or once-weekly exenatide.
Status Completed The study has finished.
Type Observational
Participants 8 people
Who can join Ages 16+ · all sexes
Timeline Started 2006-12 · est. completion 2008-02
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT00803920 ↗
Description as written by the study sponsor.
The purpose of this substudy is to obtain CGM data from individuals taking exenatide. The CGM measurements gathered before starting and during treatment with exenatide IR and/or exenatide LAR will help determine the characteristics of glucose control during treatment.
| Main thing measured | Characterize glucose control using periodic CGM in subjects participating in protocol 2993LAR-105 at the International Diabetes Center study site. |
|---|---|
| Sponsor | HealthPartners Institute |
| Conditions studied | Type 2 Diabetes Mellitus |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00803920 ↗